{"id":53880,"date":"2023-08-28T08:29:21","date_gmt":"2023-08-28T12:29:21","guid":{"rendered":"https:\/\/ifintechworld.com\/markets\/will-baxter-stock-recover-to-its-pre-inflation-shock-highs\/"},"modified":"2023-08-28T08:29:24","modified_gmt":"2023-08-28T12:29:24","slug":"will-baxter-stock-recover-to-its-pre-inflation-shock-highs","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=53880","title":{"rendered":"Will Baxter Stock Recover To Its Pre-Inflation Shock Highs?"},"content":{"rendered":"
\n

Baxter stock<\/strong> (NYSE: BAX) currently trades at $41 per share, more than 50% lower than the level seen in March 2021, and it can see higher levels over time. BAX stock was trading at around $64 in early June 2022, just before the Fed started increasing rates, and is now 35% below that level, compared to 15% gains for the S&P 500 during this period. This underperformance of Baxter stock can be attributed to its tepid sales growth of 1% in H1\u201923, and growth is expected to remain tepid in the near term. Although there has been a steady decline in the inflation rate in response to the Fed\u2019s aggressive rate hike plan, investors still have concerns about a potential recession.<\/p>\n

We note that BAX stock has had a Sharpe Ratio of -0.1<\/strong> since early 2017, which is far worse than 0.6<\/strong> for the S&P 500 Index over the same period. This compares with the Sharpe of 1.3<\/strong> for the Trefis Reinforced Value portfolio. Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds.<\/p>\n

Returning to the pre-inflation shock level of about $90 means that BAX stock will have to gain more than 115% from here, and we don\u2019t think this will materialize anytime soon. That said, there is upside potential from its current levels. BAX stock is trading at 1.4x<\/strong> revenues, compared to around 2.0x <\/strong>in late 2022. Our Baxter Valuation Ratios Comparison<\/strong> dashboard has more details.<\/p>\n

Our detailed analysis of Baxter\u2019s upside post-inflation shock<\/strong> captures trends in the company\u2019s stock during the turbulent market conditions seen over 2022. It compares these trends to the stock\u2019s performance during the 2008 recession.<\/p>\n

<\/fbs-ad><\/p>\n

2022 Inflation Shock<\/strong><\/p>\n

Timeline of Inflation Shock So Far:<\/p>\n